Chemomab Therapeutics (CMMB) Capital Expenditures (2018 - 2023)
Chemomab Therapeutics (CMMB) posted Capital Expenditures of $6000.0 for Q4 2023, up 250.0% on a QoQ basis from -$4000.0 in Q2 2023, and down 95.56% year-over-year from $135000.0 in Q4 2022.
Chemomab Therapeutics (CMMB) Capital Expenditures (2018 - 2023) Analysis & Trends
Chemomab Therapeutics' Capital Expenditures history runs 6 years deep, the most recent figure standing at $6000.0 for Q4 2023.
- Quarterly Capital Expenditures fell 95.56% year-over-year to $6000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $3000.0 (down 95.59% YoY) and the FY2025 annual result came in at $3000.0, changed N/A from the prior year.
- Capital Expenditures was $6000.0 for Q4 2023 at Chemomab Therapeutics, up from -$4000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $165000.0 in Q4 2019 and bottomed at -$161000.0 in Q3 2019.
- A 5-year average of $24611.1 and a median of $6500.0 in 2020 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2021 — Capital Expenditures surged 13300.0% — and 2022, when it sank 138.24%.
- Chemomab Therapeutics' Capital Expenditures stood at $165000.0 in 2019, then slumped by 99.39% to $1000.0 in 2020, then jumped by 13300.0% to $134000.0 in 2021, then gained by 0.75% to $135000.0 in 2022, then tumbled by 95.56% to $6000.0 in 2023.
- Business Quant data shows CMMB's Capital Expenditures at $6000.0 in Q4 2023, -$4000.0 in Q2 2023, and $1000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Chemomab Therapeutics | 124.14 Mn | 113.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 6,000.00 |
| Dec 31, 2023 | 6,000.00 |
| Jun 30, 2023 | -4,000.00 |
| Jun 30, 2023 | -4,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Dec 31, 2022 | 135,000.00 |
| Dec 31, 2022 | 135,000.00 |
| Sep 30, 2022 | -42,000.00 |
| Sep 30, 2022 | -42,000.00 |
| Jun 30, 2022 | -39,000.00 |
| Jun 30, 2022 | -39,000.00 |
| Mar 31, 2022 | 14,000.00 |
| Mar 31, 2022 | 14,000.00 |
| Dec 31, 2021 | 134,000.00 |
| Dec 31, 2021 | 134,000.00 |
| Jun 30, 2021 | 102,000.00 |
| Jun 30, 2021 | 102,000.00 |
| Mar 31, 2021 | 3,000.00 |
| Mar 31, 2021 | 3,000.00 |